---
title: "Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults: Indication questions"
description: "Indication questions on Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Eligibility. Questions: What is Prevnar 20 approved for in adults? Which Prevnar 20 pneumonia serotypes are under accelerated approval? Prevnar 20 and diabetes: what are the pneumococcal vaccination recommendations? Prevnar 20 and COPD: what are the pneumococcal vaccination recommendations? 2 further questions follow. 6 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/indication"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults: Indication questions

Manufacturer: Wyeth Pharmaceutical Division of Wyeth Holdings LLC  
Prescribing information: [Prevnar 20](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428)

Indication questions that apply to every indication of Prevnar 20 are on [Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine), all indications: Indication](https://www.evicenter.com/medical-information/prevnar-20/indication).

## Indication

<a id="prevnar20-adult-indication"></a>

### What is Prevnar 20 approved for in adults?

> “Prevnar 20® is a vaccine indicated for”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=Prevnar%2020%C2%AE%20is%20a%20vaccine%20indicated%20for)

> “active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=active%20immunization%20for%20the%20prevention%20of%20invasive%20disease%20caused%20by,weeks%20of%20age%20and%20older.)

> “active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older.”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=active%20immunization%20for%20the%20prevention%20of%20pneumonia%20caused%20by%20S.%20pneumoniae%20serotypes%201%2C%203%2C%204%2C%205%2C%206A%2C%206B%2C%207F%2C%208%2C%209V%2C%2010A%2C%2011A%2C%2012F%2C%2014%2C%2015B%2C%2018C%2C%2019A%2C%2019F%2C%2022F%2C%2023F%2C%20and%2033F%20in%20individuals%2018%20years%20of%20age%20and%20older.,-The%20indication%20for)

Note: The label also lists an otitis media indication for children 6 weeks through 5 years of age, which is outside the adult scope of this page.

<a id="prevnar20-accelerated-approval"></a>

### Which Prevnar 20 pneumonia serotypes are under accelerated approval?

> “The indication for the prevention of pneumonia caused by S. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F in individuals 18 years of age and older is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay [see Clinical Studies (14.2)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=age%20and%20older.-,The%20indication%20for%20the%20prevention%20of%20pneumonia%20caused%20by%20S.,benefit%20in%20a%20confirmatory%20trial.)

## Eligibility

<a id="prevnar20-diabetes"></a>

### Prevnar 20 and diabetes: what are the pneumococcal vaccination recommendations?

> “Recommendations for Prevnar 20<sup>®</sup> include:
> Eligible adult patients aged 19+ with diabetes<sup>1</sup>”

Source: [PREVNAR 20: Diabetes, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/patients-at-risk/diabetes#:~:text=Recommendations%20for%20Prevnar,adult%20patients%20aged%2019%2B%20with)

> “The ADA recommends vaccinating adults with diabetes against pneumococcal disease<sup>6</sup>”

Source: [PREVNAR 20: Diabetes, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/patients-at-risk/diabetes#:~:text=The%20ADA%20recommends%20vaccinating%20adults%20with%20diabetes%20against%20pneumococcal)

Note: The ADA statement concerns pneumococcal vaccination in general; the page cites the ADA Standards of Care in Diabetes 2025. The Prevnar 20 line cites the ACIP recommendations published in MMWR in 2025, which are for pneumococcal conjugate vaccination.

<a id="prevnar20-copd"></a>

### Prevnar 20 and COPD: what are the pneumococcal vaccination recommendations?

> “Recommendations for Prevnar 20<sup>®</sup> include:
> Eligible adult patients aged 19+ with chronic lung disease, including COPD<sup>1</sup>”

Source: [PREVNAR 20: COPD, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/patients-at-risk/copd#:~:text=Recommendations%20for%20Prevnar,with%20chronic%20lung%20disease%2C%20including)

> “The ALA recommends vaccinating against pneumococcal pneumonia for patients at increased risk<sup>6</sup>”

Source: [PREVNAR 20: COPD, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/patients-at-risk/copd#:~:text=The%20ALA%20recommends%20vaccinating%20against%20pneumococcal%20pneumonia%20for%20patients%20at%20increased)

Note: The ALA statement concerns pneumococcal vaccination of patients at increased risk of pneumococcal pneumonia in general; the page cites the ALA web page Preventing pneumonia, updated June 3, 2025. The Prevnar 20 line cites the ACIP recommendations published in MMWR in 2025, which are for pneumococcal conjugate vaccination.

<a id="prevnar20-asthma"></a>

### Prevnar 20 and asthma: what are the pneumococcal vaccination recommendations?

> “Recommendations for Prevnar 20<sup>®</sup> include:
> Eligible adult patients aged 19+ with asthma<sup>1</sup>”

Source: [PREVNAR 20: Asthma, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/patients-at-risk/asthma#:~:text=Recommendations%20for%20Prevnar,adult%20patients%20aged%2019%2B%20with)

> “The AAFA supports vaccinating adults with asthma against pneumococcal disease<sup>6</sup>”

Source: [PREVNAR 20: Asthma, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/patients-at-risk/asthma#:~:text=The%20AAFA%20supports%20vaccinating%20adults%20with%20asthma%20against%20pneumococcal)

Note: The AAFA statement concerns pneumococcal vaccination in general; the page cites the AAFA vaccine recommendations page, reviewed February 2017. The Prevnar 20 line cites the ACIP recommendations published in MMWR in 2025, which are for pneumococcal conjugate vaccination.

<a id="prevnar20-chronic-heart-disease"></a>

### Prevnar 20 and chronic heart disease: what are the pneumococcal vaccination recommendations?

> “Recommendations for Prevnar 20<sup>®</sup> include:
> Eligible adult patients aged 19+ with chronic heart disease<sup>1</sup>”

Source: [PREVNAR 20: Chronic Heart Disease, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/patients-at-risk/chronic-heart-disease#:~:text=Recommendations%20for%20Prevnar,aged%2019%2B%20with%20chronic%20heart)

> “AHA, ACC, and HFSA recommend adult patients with heart failure be vaccinated against respiratory illnesses according to their 2022 guidelines<sup>5¶</sup>”

Source: [PREVNAR 20: Chronic Heart Disease, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/patients-at-risk/chronic-heart-disease#:~:text=AHA%2C%20ACC%2C%20and%20HFSA%20recommend,illnesses%20according%20to%20their%202022)

> “<sup>¶</sup>This is a moderate recommendation with moderate-quality evidence from 1 or more well-designed, well-executed, nonrandomized studies, observational studies, or registry studies.<sup>5</sup>”

Source: [PREVNAR 20: Chronic Heart Disease, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/patients-at-risk/chronic-heart-disease#:~:text=is%20a%20moderate%20recommendation%20with,studies%2C%20observational%20studies%2C%20or%20registry)

Note: The 2022 AHA/ACC/HFSA guideline statement concerns adults with heart failure and vaccination against respiratory illnesses in general. The Prevnar 20 line cites the ACIP recommendations published in MMWR in 2025, which are for pneumococcal conjugate vaccination.

## Related pages
- [Medical information: Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine): Pneumococcal disease prevention in adults](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults)
- [Clinical trials](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/safety)
- [Specific populations](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/guidelines)
